NCT05226728View on ClinicalTrials.gov

Pharmacokinetically-guided on the Individualization of Pembrolizumab Administration in the Treatment of Lung Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

October 10, 2018

Primary Completion Date

February 1, 2021

Study Completion Date

February 1, 2021

Conditions
Non-small Cell Lung Cancer
Interventions
DRUG

pembrolizumab

Eligible patients received pembrolizumab 200mg every 3 weeks with or without chemotherapy for four cycles, then for patients without progressive disease, pembrolizumab was administrated in new dose-intervals according to steady state plasma-concentration (Css) of pembrolizumab until disease progression

Trial Locations (1)

510000

Sun Yat-sen University Cancer Center, Guangzhou

All Listed Sponsors
lead

Sun Yat-sen University

OTHER

NCT05226728 - Pharmacokinetically-guided on the Individualization of Pembrolizumab Administration in the Treatment of Lung Cancer | Biotech Hunter | Biotech Hunter